GlycoMimetics EBITDA 2012-2025 | CBIO
GlycoMimetics ebitda from 2012 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
GlycoMimetics Annual EBITDA
(Millions of US $) |
| 2024 |
$-40 |
| 2023 |
$-39 |
| 2022 |
$-47 |
| 2021 |
$-63 |
| 2020 |
$-51 |
| 2019 |
$-61 |
| 2018 |
$-51 |
| 2017 |
$-34 |
| 2016 |
$-32 |
| 2015 |
$-13 |
| 2014 |
$-11 |
| 2013 |
$-10 |
| 2012 |
$4 |
| 2011 |
$-6 |
GlycoMimetics Quarterly EBITDA
(Millions of US $) |
| 2025-03-31 |
$-2 |
| 2024-12-31 |
$-7 |
| 2024-09-30 |
$-11 |
| 2024-06-30 |
$-10 |
| 2024-03-31 |
$-11 |
| 2023-12-31 |
$-10 |
| 2023-09-30 |
$-10 |
| 2023-06-30 |
$-9 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-11 |
| 2022-09-30 |
$-9 |
| 2022-06-30 |
$-13 |
| 2022-03-31 |
$-15 |
| 2021-12-31 |
$-17 |
| 2021-09-30 |
$-17 |
| 2021-06-30 |
$-14 |
| 2021-03-31 |
$-14 |
| 2020-12-31 |
$-16 |
| 2020-09-30 |
$-14 |
| 2020-06-30 |
$-14 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
$-15 |
| 2019-09-30 |
$-14 |
| 2019-06-30 |
$-17 |
| 2019-03-31 |
$-15 |
| 2018-12-31 |
$-15 |
| 2018-09-30 |
$-12 |
| 2018-06-30 |
$-12 |
| 2018-03-31 |
$-12 |
| 2017-12-31 |
$-9 |
| 2017-09-30 |
$-8 |
| 2017-06-30 |
$-8 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$-8 |
| 2016-06-30 |
$-8 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-9 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$10 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-7 |
| 2014-09-30 |
$-7 |
| 2014-06-30 |
$8 |
| 2014-03-31 |
$-5 |
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-4 |
| 2013-06-30 |
$-3 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| OncoCyte (IMDX) |
United States |
$0.090B |
0.00 |
